Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China
Background and Aims. There is scarcity of data in literature regarding the treatment response to sofosbuvir- (SOF-) based therapies in Chinese patients with chronic Hepatitis C Virus (HCV) infection. The aim of this study was to evaluate the efficacy and safety of SOF-based regimens for chronic hepa...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Canadian Journal of Gastroenterology and Hepatology |
| Online Access: | http://dx.doi.org/10.1155/2018/3908767 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563622623051776 |
|---|---|
| author | Chengguang Hu Guosheng Yuan Junwei Liu Huaping Huang Yanyu Ren Yinping Li Xuefu Chen Wei Li Tao Wu Hong Deng Yanzhong Peng Yong-Yuan Zhang Yuanping Zhou |
| author_facet | Chengguang Hu Guosheng Yuan Junwei Liu Huaping Huang Yanyu Ren Yinping Li Xuefu Chen Wei Li Tao Wu Hong Deng Yanzhong Peng Yong-Yuan Zhang Yuanping Zhou |
| author_sort | Chengguang Hu |
| collection | DOAJ |
| description | Background and Aims. There is scarcity of data in literature regarding the treatment response to sofosbuvir- (SOF-) based therapies in Chinese patients with chronic Hepatitis C Virus (HCV) infection. The aim of this study was to evaluate the efficacy and safety of SOF-based regimens for chronic hepatitis C (CHC) patients without cirrhosis in a real-world setting in mainland China. Methods. A total of 226 patients receiving SOF plus daclatasvir (DCV), ledipasvir (LDV), or velpatasvir (VEL) were enrolled from December 2014 to June 2017. The primary observation point was the percentage of patients with a sustained virologic response (SVR) at posttreatment week 12 (SVR12), and all adverse events were monitored during treatment and follow-up period. Results. The overall SVR12 rate was 96% (216/226), and individual SVR12 ranged from 93% to 100% in different treatment groups. No significant differences of efficacy were detected between genotypes 1b and 6a (98% for GT 1b versus 100% for GT 6a, P=0.322). Comparing the high success rates in GT 1b and 6a patients, SVR12 was relatively low in GT 3a and 3b patients. A significant difference in efficacy was observed between GT 3 and not GT 3 patients (77% versus 98%, respectively, P<0.001). No significant differences in efficacy were detected among different regimens (93% versus 97% versus 100%, respectively, P=0.153), gender (95% for male versus 96% for female, P=0.655), or baseline HCV RNA lever (96% versus 95%, respectively, P=0.614). Similar SVR rates were also obtained in naïve and previously treated patients (98% versus 93%, respectively, P=0.100). Conclusions. NS5B polymerase inhibitor SOF plus one of the NS5A inhibitors, such as DCV, LDV, or VEL for 12 weeks was associated with high SVR12 rates and well tolerated in HCV-infected patients without cirrhosis. Moreover, patients with DAAs failure should be retreated with more effective regimens like SOF/VEL. |
| format | Article |
| id | doaj-art-275714c63a8b4b7e91736df76442181a |
| institution | Kabale University |
| issn | 2291-2789 2291-2797 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology and Hepatology |
| spelling | doaj-art-275714c63a8b4b7e91736df76442181a2025-02-03T01:12:58ZengWileyCanadian Journal of Gastroenterology and Hepatology2291-27892291-27972018-01-01201810.1155/2018/39087673908767Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in ChinaChengguang Hu0Guosheng Yuan1Junwei Liu2Huaping Huang3Yanyu Ren4Yinping Li5Xuefu Chen6Wei Li7Tao Wu8Hong Deng9Yanzhong Peng10Yong-Yuan Zhang11Yuanping Zhou12Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, ChinaDepartment of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, ChinaDepartment of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, ChinaDepartment of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, ChinaDepartment of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, ChinaDepartment of Infectious Diseases, Peking University Shenzhen Hospital, Shenzhen, Guangdong, ChinaDepartment of Infectious Diseases, Guangdong Provincial People’s Hospital, Guangzhou, ChinaDepartment of Infectious Diseases, Henan Provincial People’s Hospital, Zhengzhou, Henan Province, ChinaDepartment of Infectious Disease, Hainan General Hospital, Haikou City, Hainan Province, ChinaDepartment of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, ChinaDepartment of Infectious Diseases, Peking University Shenzhen Hospital, Shenzhen, Guangdong, ChinaHBVtech, Germantown, Maryland, MD 20874, USADepartment of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, ChinaBackground and Aims. There is scarcity of data in literature regarding the treatment response to sofosbuvir- (SOF-) based therapies in Chinese patients with chronic Hepatitis C Virus (HCV) infection. The aim of this study was to evaluate the efficacy and safety of SOF-based regimens for chronic hepatitis C (CHC) patients without cirrhosis in a real-world setting in mainland China. Methods. A total of 226 patients receiving SOF plus daclatasvir (DCV), ledipasvir (LDV), or velpatasvir (VEL) were enrolled from December 2014 to June 2017. The primary observation point was the percentage of patients with a sustained virologic response (SVR) at posttreatment week 12 (SVR12), and all adverse events were monitored during treatment and follow-up period. Results. The overall SVR12 rate was 96% (216/226), and individual SVR12 ranged from 93% to 100% in different treatment groups. No significant differences of efficacy were detected between genotypes 1b and 6a (98% for GT 1b versus 100% for GT 6a, P=0.322). Comparing the high success rates in GT 1b and 6a patients, SVR12 was relatively low in GT 3a and 3b patients. A significant difference in efficacy was observed between GT 3 and not GT 3 patients (77% versus 98%, respectively, P<0.001). No significant differences in efficacy were detected among different regimens (93% versus 97% versus 100%, respectively, P=0.153), gender (95% for male versus 96% for female, P=0.655), or baseline HCV RNA lever (96% versus 95%, respectively, P=0.614). Similar SVR rates were also obtained in naïve and previously treated patients (98% versus 93%, respectively, P=0.100). Conclusions. NS5B polymerase inhibitor SOF plus one of the NS5A inhibitors, such as DCV, LDV, or VEL for 12 weeks was associated with high SVR12 rates and well tolerated in HCV-infected patients without cirrhosis. Moreover, patients with DAAs failure should be retreated with more effective regimens like SOF/VEL.http://dx.doi.org/10.1155/2018/3908767 |
| spellingShingle | Chengguang Hu Guosheng Yuan Junwei Liu Huaping Huang Yanyu Ren Yinping Li Xuefu Chen Wei Li Tao Wu Hong Deng Yanzhong Peng Yong-Yuan Zhang Yuanping Zhou Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China Canadian Journal of Gastroenterology and Hepatology |
| title | Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China |
| title_full | Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China |
| title_fullStr | Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China |
| title_full_unstemmed | Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China |
| title_short | Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China |
| title_sort | sofosbuvir based therapies for patients with hepatitis c virus infection real world experience in china |
| url | http://dx.doi.org/10.1155/2018/3908767 |
| work_keys_str_mv | AT chengguanghu sofosbuvirbasedtherapiesforpatientswithhepatitiscvirusinfectionrealworldexperienceinchina AT guoshengyuan sofosbuvirbasedtherapiesforpatientswithhepatitiscvirusinfectionrealworldexperienceinchina AT junweiliu sofosbuvirbasedtherapiesforpatientswithhepatitiscvirusinfectionrealworldexperienceinchina AT huapinghuang sofosbuvirbasedtherapiesforpatientswithhepatitiscvirusinfectionrealworldexperienceinchina AT yanyuren sofosbuvirbasedtherapiesforpatientswithhepatitiscvirusinfectionrealworldexperienceinchina AT yinpingli sofosbuvirbasedtherapiesforpatientswithhepatitiscvirusinfectionrealworldexperienceinchina AT xuefuchen sofosbuvirbasedtherapiesforpatientswithhepatitiscvirusinfectionrealworldexperienceinchina AT weili sofosbuvirbasedtherapiesforpatientswithhepatitiscvirusinfectionrealworldexperienceinchina AT taowu sofosbuvirbasedtherapiesforpatientswithhepatitiscvirusinfectionrealworldexperienceinchina AT hongdeng sofosbuvirbasedtherapiesforpatientswithhepatitiscvirusinfectionrealworldexperienceinchina AT yanzhongpeng sofosbuvirbasedtherapiesforpatientswithhepatitiscvirusinfectionrealworldexperienceinchina AT yongyuanzhang sofosbuvirbasedtherapiesforpatientswithhepatitiscvirusinfectionrealworldexperienceinchina AT yuanpingzhou sofosbuvirbasedtherapiesforpatientswithhepatitiscvirusinfectionrealworldexperienceinchina |